Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | FABP4 | P15090 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.50 |
| ▸ | FABP3 | P05413 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16266063 | 0.90 | TBXA2R (0.60) | TBXA2RPTGDRCA1CA2KDM4E | |
| SCHEMBL11828582 | 0.81 | HTR6 (0.60) | CA1CA2FABP4HDAC6FABP3 | |
| SCHEMBL5944434 | 0.80 | TBXA2R (0.57) | TBXA2RPTGDRCA1CA2KDM4E | |
| SCHEMBL9518655 | 0.80 | TBXA2R (0.57) | TBXA2RPTGDRCA1CA2KDM4E | |
| SCHEMBL9521476 | 0.77 | TBXA2R (1.00) | TBXA2RPTGDR | |
| SCHEMBL8381134 | 0.77 | HDAC6 (0.50) | TBXA2RPTGDRCA1CA2KDM4E | |
| SCHEMBL11822804 | 0.76 | TBXA2R (0.63) | TBXA2RPTGDRCA1CA2HTR6 | |
| SCHEMBL11822791 | 0.76 | TBXA2R (0.60) | TBXA2RPTGDRCA1CA2MEN1 | |
| Acetic Acid SCHEMBL9518648 | 0.75 | CA1 (0.78) | CA1CA2KDM4EMEN1GLA | |
| SCHEMBL29966259 | 0.74 | HTR6 (0.58) | CA1CA2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110104177-A1 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-08-19 | — | — | US | disclosed |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090022694-A1 | SIRT1 INHIBITION | ELIXIR PHARMACEUTICALS, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080214800-A1 | Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders | ELIXIR PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20050256181-A1 | Treating a viral disorder | ELIXIR PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050209300-A1 | Methods of treating a disorder | IPSOL AG (LI) | 2005-09-22 | — | — | US | disclosed |
| EP-0239306-B1 | TETRAHYDROCARBAZOLE ESTERS | MERCK FROSST CANADA INC. (CA) | 1993-06-02 | — | — | EP | disclosed |
| EP-0234708-B1 | TETRAHYDROCARBAZOLE 1-ALKANOIC ACIDS | MERCK FROSST CANADA INC. (CA) | 1991-02-27 | — | — | EP | disclosed |
| US-4940719-A | Tetrahydrocarbazole esters, pharmaceutical compositions and use | MERCK FROSST CANADA, INC. (CA) | 1990-07-10 | — | — | US | disclosed |
| US-4906654-A | Cyclohept[b]indoleakanoic acids, pharmaceutical compositions and use | MERCK FROSST CANADA, INC. (CA) | 1990-03-06 | — | — | US | disclosed |
| EP-0310179-A2 | Tetrahydrocarbazole esters | MERCK FROSST CANADA INC. (CA) | 1989-04-05 | — | — | EP | disclosed |
| US-4808608-A | ANTIALLERGENS, HYPOTENSIVE AGENT, ANTICOAGULANT | MERCK & CO., INC. (US) | 1989-02-28 | — | — | US | disclosed |
| EP-0304156-A1 | Cyclohept b indolealkanoic acids | MERCK FROSST CANADA INC. (CA) | 1989-02-22 | — | — | EP | disclosed |
| EP-0300676-A2 | Tetrahydrocarbazole 1-alkanoic acids | MERCK FROSST CANADA INC. (CA) | 1989-01-25 | — | — | EP | disclosed |
| US-4775680-A | PROSTAGLANDIN ANTAGONISTS | MERCK & CO., INC. (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0239306-A2 | Tetrahydrocarbazole esters | MERCK FROSST CANADA INC. (CA) | 1987-09-30 | — | — | EP | disclosed |
| EP-0234708-A1 | Tetrahydrocarbazole 1-alkanoic acids | MERCK FROSST CANADA INC. (CA) | 1987-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113903-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | TBXA2R 3930/4885PTGDR 4189/4885CA1 4771/4885 |
| US-20080214800-A1 | Deacetylase which uses NAD as a cofactor; treating sirtuin related disorders | SIRT3, SIRT1, SIRT2 | TBXA2R 2805/4885PTGDR 3358/4885CA1 4610/4885 |
| US-20100210692-A1 | METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS | SIRT1, SIRT2, SIRT3 | TBXA2R 2901/4885PTGDR 4127/4885CA1 4090/4885 |
| US-20090022694-A1 | SIRT1 INHIBITION | SIRT1, SIRT2, SIRT3 | TBXA2R 1932/4885PTGDR 3815/4885CA1 2046/4885 |
| US-20110104177-A1 | HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE | HDAC1, HDAC5, HDAC4 | TBXA2R 4625/4885PTGDR 4325/4885CA1 2399/4885 |
| US-20140163029-A1 | SirT INHIBITORS THAT BIND TO NAD | SIRT1, SIRT3, SIRT2 | TBXA2R 3930/4885PTGDR 4189/4885CA1 4771/4885 |
| US-20050209300-A1 | Methods of treating a disorder | CPT1B, CYP27A1, CLN6 | TBXA2R 2830/4885PTGDR 2085/4885CA1 2767/4885 |
| US-20090306168-A1 | SirT Inhibitors That Bind to NAD | SIRT1, SIRT3, SIRT2 | TBXA2R 3930/4885PTGDR 4189/4885CA1 4771/4885 |
| US-20050256181-A1 | Treating a viral disorder | HAVCR2, EIF2AK2, RPL35 | TBXA2R 2600/4885PTGDR 2538/4885CA1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.